What Are The Physiological Mechanisms Of 595-Nm Pulsed Dye Lasers (Pdl) In Suppressing Hypertrophic Scar And Keloid Growth? Understand How Pdl Targets Vessels To Reduce Scar Activity

595-nm pulsed dye lasers (PDL) suppress hypertrophic scars and keloids primarily by selectively photothermolysing their abnormal microvasculature. Hemoglobin absorbs the laser energy, converting it into heat that injures small scar vessels and reduces erythema, vascular congestion, and local inflammatory signaling. These vascular effects can be followed by changes in fibroblast activity, collagen turnover, and profibrotic signaling, which may gradually flatten and soften the scar.

PDL is best understood as a vascular and inflammatory modulator, not as a laser that simply “burns away” scar tissue. Its effects on perfusion, cytokine signaling, fibroblasts, and extracellular-matrix remodeling work together over multiple treatment sessions.

How 595-nm PDL Interacts With Scar Tissue

Selective absorption by hemoglobin

The 595-nm wavelength is strongly absorbed by oxyhemoglobin and deoxyhemoglobin within superficial blood vessels. Hypertrophic scars and keloids commonly contain enlarged, dense, or abnormal microvessels, making these structures preferential targets.

The surrounding nonvascular tissue absorbs substantially less energy during a properly delivered pulse. This allows PDL to produce a localized vascular effect while limiting unwanted injury to the epidermis and adjacent dermis.

Conversion of light into heat

Absorbed laser energy is converted into thermal energy within the blood column and vessel wall. When the temperature and exposure time are sufficient, the vessel wall undergoes coagulative injury, and the vessel may thrombose, collapse, or become occluded.

This process is called selective photothermolysis. The goal is to damage the target vessel while keeping heat diffusion into surrounding tissue within a tolerable range.

Reduction of scar erythema

The immediate visible effect is often a reduction in redness caused by excessive superficial blood flow and dilated vessels. PDL can also reduce telangiectasia and the vascular component of recently formed hypertrophic scars.

Redness reduction does not necessarily mean that all fibrotic tissue has been removed. Scar thickness, stiffness, and symptoms may improve more gradually than color.

How Vascular Injury May Reduce Fibrosis

Reduced perfusion and altered oxygen signaling

Vessel coagulation and occlusion reduce blood flow through selected scar microvessels. This changes the local oxygen, nutrient, and inflammatory environment.

Localized hypoxia may contribute to remodeling, but it should not be treated as the sole or universally proven explanation for PDL’s clinical effect. Excessive vascular injury can also delay healing, so treatment must remain controlled.

Suppression of profibrotic signaling

PDL treatment has been associated in some studies with reduced expression of profibrotic mediators, including transforming growth factor beta 1 (TGF-β1) and connective tissue growth factor (CTGF).

These mediators help maintain fibroblast activation and excessive extracellular-matrix production. Reducing their activity may shift the scar environment away from persistent collagen deposition.

Effects on fibroblast behavior

Activated fibroblasts and myofibroblasts are central to hypertrophic scar and keloid formation. They produce collagen and other matrix components and can generate contractile forces that contribute to scar stiffness.

PDL-related thermal and biochemical changes may reduce fibroblast proliferation and, in some contexts, promote fibroblast or myofibroblast apoptosis. The magnitude of this effect varies with scar age, thickness, vascularity, fluence, pulse duration, and treatment schedule.

How Matrix Remodeling Occurs

Increased collagen turnover

Scar improvement requires a balance between collagen production and collagen degradation. PDL has been associated with increased activity or expression of matrix metalloproteinases (MMPs), enzymes that break down components of the extracellular matrix.

When matrix degradation becomes more active relative to new collagen synthesis, dense scar tissue can gradually soften and reorganize. This is a remodeling process that develops over time rather than an instant dissolution of the scar.

Collagen reorganization

Thermal exposure may alter the mechanical organization of collagen and contribute to fiber relaxation or realignment. However, the claim that clinical PDL treatment routinely produces “thermal dissolution” of collagen disulfide bonds is an oversimplification and is not the principal established mechanism.

At appropriate settings, PDL is primarily a non-ablative vascular treatment. Excessive heating can damage surrounding tissue and increase the risk of adverse healing rather than improve collagen architecture.

Progressive rather than immediate flattening

Because collagen degradation and matrix reorganization are biologic processes, flattening usually requires serial treatments. Vascular scars may respond more readily than pale, mature, or highly fibrotic scars with relatively little active microvasculature.

Keloids can also continue growing beyond the original wound boundaries, so PDL alone may be insufficient for durable control.

How Inflammation Is Modulated

Reduction of inflammatory activity

Hypertrophic scars and keloids are maintained partly by persistent inflammatory signaling. Vascular injury from PDL can reduce the abnormal microvascular and inflammatory environment that supports ongoing fibroblast activation.

This may help explain improvements in redness, itch, tenderness, and sometimes scar thickness.

Possible effects on mast cells

Some reports describe reductions in mast-cell density or activity after PDL treatment. Because mast cells can release histamine and other mediators that influence vascular permeability and inflammation, their modulation could contribute to symptom improvement.

This mechanism remains less firmly established than hemoglobin targeting and vascular photothermolysis. It should be viewed as a potential secondary pathway rather than the primary explanation for every clinical response.

Changes in angiogenic signaling

The abnormal vasculature of a scar can support ongoing inflammatory and fibrotic activity. PDL may reduce angiogenic signaling, including pathways involving vascular endothelial growth factor (VEGF), although the strength and consistency of this evidence depend on the specific scar and study design.

The clinically relevant result is a less vascular, less erythematous microenvironment that may be less supportive of continued scar activity.

Why Scar Type and Treatment Parameters Matter

Vascular scars are more responsive

PDL is generally most useful when a scar is red, raised, and visibly vascular. Early hypertrophic scars often have a stronger vascular component than long-standing, pale, rigid scars.

A mature scar with extensive fibrosis but minimal erythema may require another modality or combination treatment aimed more directly at remodeling the dense collagen matrix.

Fluence and pulse duration determine the effect

The laser must deliver enough energy to injure abnormal vessels without producing excessive nonspecific heating. Fluence, pulse duration, spot size, cooling, and the interval between sessions all influence the balance between efficacy and adverse effects.

Treatment is typically titrated to the scar’s vascularity, thickness, and response. A single fixed energy density is not appropriate for every patient or every scar.

Repeated treatment supports remodeling

Vascular closure and inflammatory modulation occur after individual sessions, but matrix remodeling takes longer. Serial, appropriately spaced treatments allow the clinician to reassess vascular response and adjust parameters.

Non-overlapping coverage helps avoid excessive energy accumulation in one region and reduces the risk of unnecessary thermal injury.

Understanding the Trade-offs

PDL does not remove the keloid immediately

PDL can reduce redness and may soften or flatten a scar, but it does not excise the lesion or instantly eliminate established collagen. Thick keloids frequently need combination therapy, such as intralesional corticosteroids or other clinician-selected treatments.

PDL should therefore be considered part of a scar-management strategy rather than a guaranteed standalone cure.

Recurrence remains possible

Keloids have a biologic tendency to recur. Reducing vascularity and profibrotic signaling may lower activity or improve appearance, but PDL cannot reliably eliminate the underlying recurrence risk.

Claims that PDL universally prevents keloid recurrence are too strong. Outcomes depend on lesion biology, treatment timing, combination therapy, and individual healing behavior.

Adverse effects reflect excessive or poorly targeted heating

Expected reactions can include transient purpura, swelling, redness, and tenderness. More significant complications may include blistering, pigmentary change, prolonged inflammation, or delayed healing.

These risks are particularly relevant in darker skin types or when treatment parameters are too aggressive. Cooling, conservative titration, and careful assessment of skin type and scar characteristics are important.

Pigment and texture respond differently

PDL is especially effective for vascular color. Texture, thickness, stiffness, and contracture may respond more slowly and less completely.

A reduction in erythema should therefore be evaluated separately from improvement in elevation, pliability, symptoms, and recurrence.

Making the Right Choice for Your Goal

PDL is most rational when the scar’s vascular and inflammatory components are prominent and the treatment plan accounts for its limitations.

If your primary focus is reducing redness: PDL directly targets hemoglobin-rich abnormal vessels and is most predictably useful for erythematous, vascular scars.
If your primary focus is flattening a raised scar: Expect gradual improvement through vascular and fibroblast modulation, with combination treatment often needed for thick hypertrophic scars or keloids.
If your primary focus is reducing itch or tenderness: PDL may help by decreasing vascular and inflammatory signaling, but symptom response is variable and should be monitored independently of cosmetic change.
If your primary focus is preventing keloid recurrence: Use PDL as one component of a broader, clinician-directed prevention plan rather than relying on vascular treatment alone.

Understanding PDL as a controlled intervention on scar blood vessels, inflammation, and matrix remodeling provides the clearest basis for choosing it, setting expectations, and combining it appropriately with other treatments.

Summary Table:

Mechanism	Description
Selective photothermolysis	Hemoglobin absorbs 595 nm light, causing localized vascular injury without damaging surrounding tissue.
Reduced erythema	Vasculature occlusion decreases redness and telangiectasia.
Suppressed profibrotic signaling	Decreased TGF-β1 and CTGF reduce fibroblast activation and collagen deposition.
Increased matrix remodeling	MMP activity rises, promoting collagen breakdown and reorganization.
Modulated inflammation	Reduced inflammatory and angiogenic signaling lowers itch, tenderness, and support for scar growth.

Enhance your clinic's scar management with BELIS' advanced medical aesthetic devices. Our PDL systems offer precise vascular targeting for hypertrophic scars and keloids, backed by robust OEM/ODM support and international certifications. Contact us today to expand your treatment portfolio and meet patient demand with reliable, high-performance technology. Contact us for partnership opportunities.